Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Nearly $200 million of the pledge will go to DREAMS programs in Africa and the Caribbean.
An early trial of Gilead’s HIV capsid inhibitor supports three-month dosing.
Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.
A decade of aging brings on heart and kidney troubles in people with HIV.
A study finds that CD4 cells decline after people with HIV contract hepatitis C.
A look at 2009 to 2014 data found that those in care for HIV saw a considerable fall in treatment deferrals.
Treatment efficacy has steadily improved since effective combination HIV therapy first entered advanced clinical trials in the mid-1990s.
For over 30 years, the California-based group fought for treatments, research, education and quality health care.
Fostemsavir offers HIV treatment hope to those with no other options.
Periodic infusions of long-acting HIV antibodies may eventually become a new way of treating the virus.
December 2018 Survey
Promising findings from a study of a two-drug injectable treatment given every four weeks.
NMAC offers support and engagement opportunities to advocates living with HIV who are 50 and over.
Aprende más sobre la prevención y el tratamiento del VIH para mantenerse saludable.
“This is life or death. This is unacceptable.”
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.